Literature DB >> 31128449

Development of selective small molecule MDM2 degraders based on nutlin.

Bo Wang1, Suzhen Wu2, Jin Liu1, Ka Yang1, Haibo Xie1, Weiping Tang3.   

Abstract

Tumor suppressor protein p53 is important to the regulation of many cellular processes and the prevention of cancer development. In some cancer cells, the function of p53 is inhibited by murine double minute 2 protein (MDM2). To restore the function of p53, the inhibition or depletion of MDM2 has become a potential therapeutic treatment. We have successfully developed a series of small molecule MDM2 degraders that can promote the proteolysis of MDM2 oncoprotein, thus reactivating tumor suppressor p53. The superior degrader features a nutlin-based MDM2 ligand and a lenalidomide-based cereblon E3 ubiquitin ligase ligand with a short linker between the two ligands. At low nanomolar concentrations in RS4; 11 leukemia cells, this degrader promotes efficient degradation of MDM2. It also inhibits the proliferation of leukemia cells with an IC50 value of 3.2 nM and induces apoptosis effectively. All of these data indicate that MDM2 degraders are promising therapeutics for the treatment of cancers, such as leukemia.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Degraders; Induced protein degradation; MDM2; PROTACs; p53

Mesh:

Substances:

Year:  2019        PMID: 31128449     DOI: 10.1016/j.ejmech.2019.05.046

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  16 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

2.  Targeted Degradation of the Oncogenic Phosphatase SHP2.

Authors:  Vidyasiri Vemulapalli; Katherine A Donovan; Tom C M Seegar; Julia M Rogers; Munhyung Bae; Ryan J Lumpkin; Ruili Cao; Matthew T Henke; Soumya S Ray; Eric S Fischer; Gregory D Cuny; Stephen C Blacklow
Journal:  Biochemistry       Date:  2021-08-19       Impact factor: 3.162

Review 3.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 4.  Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:  Haohao Zhu; Hui Gao; Yingying Ji; Qin Zhou; Zhiqiang Du; Lin Tian; Ying Jiang; Kun Yao; Zhenhe Zhou
Journal:  J Hematol Oncol       Date:  2022-07-13       Impact factor: 23.168

5.  A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Authors:  Ka Yang; Yu Zhao; Xueqing Nie; Hao Wu; Bo Wang; Chelsi M Almodovar-Rivera; Haibo Xie; Weiping Tang
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

6.  Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.

Authors:  Bo Wang; Jin Liu; Ira Tandon; Suzhen Wu; Peng Teng; Jianhua Liao; Weiping Tang
Journal:  Eur J Med Chem       Date:  2021-04-04       Impact factor: 7.088

7.  Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.

Authors:  Shipeng He; Junhui Ma; Yuxin Fang; Ying Liu; Shanchao Wu; Guoqiang Dong; Wei Wang; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2020-12-02       Impact factor: 11.413

Review 8.  E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.

Authors:  Aleša Bricelj; Christian Steinebach; Robert Kuchta; Michael Gütschow; Izidor Sosič
Journal:  Front Chem       Date:  2021-07-05       Impact factor: 5.221

9.  Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).

Authors:  Zhimin Zhang; Xinyue Chang; Chixiao Zhang; Shenxin Zeng; Meihao Liang; Zhen Ma; Zunyuan Wang; Wenhai Huang; Zhengrong Shen
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 10.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.